1st Counsel – Lifestyle
Author:
HOTH THERAPEUTICS, INC.
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
April 14, 2026
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
April 13, 2026
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
April 2, 2026
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
April 1, 2026
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
April 1, 2026
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
March 31, 2026
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
March 26, 2026
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
March 24, 2026
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
March 10, 2026